NCT02013349已完成不适用
POST-MARKET EVALUATION OF DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 102
- 试验地点
- 14
- 主要终点
- Major Adverse Cardiac Events (MACE)
研究概览
简要总结
To evaluate the long-term safety and performance of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
详细描述
DESolve is not currently approved for sale in the United States.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be at least 18 years of age
- •Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the DESolve NE BCSS and he/she provides written informed consent, as approved by the appropriate Ethics Committee of the respective clinical site, prior to any clinical study related procedure
- •Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
- •Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery
- •Patient must agree to undergo all clinical study required follow-up visits
- •Patient must agree not to participate in any other clinical study for a period of two years following the index procedure
- •Angiographic Inclusion Criteria - Target Lesion/Vessel Target lesion must be located in a native coronary artery with a nominal vessel diameter of between 2.75 and 3.5 mm assessed by visual estimation or QCA
- •Target lesion must measure ≤ 24 mm in length
- •Target lesion must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 90% with a TIMI flow of ≥ 1
- •Percutaneous intervention of lesions in the target vessel if:
- •Not part of a clinical investigation
- •≥ 6 months prior to the study index procedure
- •≥ 9 months after the study index procedure (planned)
- •Previous intervention was distal to and > 10 mm from the target lesion
排除标准
- •Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure and CK and CK-MB have not returned within normal limits at the time of procedure
- •Patient is currently experiencing clinical symptoms consistent with AMI
- •Patient requires the use of any rotablator intervention during the index procedure
- •Patient has current unstable arrhythmias
- •Patient has a known left ventricular ejection fraction (LVEF) < 30%
- •Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant
- •Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure
- •Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus)
- •Patient is receiving chronic anticoagulation therapy (e.g., heparin, Coumadin) that cannot be stopped and restarted according to local hospital standard procedures
- •Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
- •Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel
- •Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected liver disease
- •Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, or patient on dialysis)
- •Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
- •Patient has had a significant GI or urinary bleed within the past six months
- •Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion
- •Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
- •Patient is already participating in another clinical study
- •Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal (defined as amenorrheic for at least one year) as well as women who are pregnant or nursing
- •Patient is unable to give their consent, is legally incompetent, or is institutionalized by virtue of an order issued by the courts or other authority
- •Angiographic Exclusion Criteria - Target Lesion/Vessel
- •Target lesion(s) meets any of the following criteria:
- •Aorto-ostial location
- •Left main location
- •Located within 5 mm of the origin of the LAD or LCX
- •Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft
- •Lesion involving a side branch >2mm in diameter or bifurcation
- •Previous placement of a scaffold proximal to or within 10 mm of the target lesion
- •Total occlusion (TIMI flow 0), or sub-total occlusion (TIMI flow 1)
- •Excessive tortuosity proximal to or within the lesion
- •Angulation (≥ 45o) proximal to or within the lesion
- •Calcification moderate or heavy
- •Previous intervention restenosis
结局指标
主要结局
Major Adverse Cardiac Events (MACE)
时间窗: 5 years
Major Adverse Cardiac Events (MACE) is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization
次要结局
未报告次要终点
研究者
研究点 (14)
Loading locations...
相似试验
招募中
3 期
Effectiveness of Detoxil capsules in metabolic syndromeMetabolic syndrome.Metabolic syndromeE88.81IRCT20080901001165N65Tabib daru pharmaceutical company100
终止
3 期
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsAcromegalyNCT00642421Ambrilia Biopharma, Inc.40
招募中
3 期
Evaluation of efficacy and safety of Detoxil capsules in patients with liver injuryIRCT20080901001165N68Bagheiat-allah University of Medical Sciences100
招募中
1 期
hydrogel effectiveness in the treatment of skin wrinklesskin wrinkles.Other specified disorders of the skin and subcutaneous tissueL98.8IRCT20210612051545N2Tehran University of Medical Sciences20
招募中
不适用
Safety and efficacy of abluminal biodegradable polymer sirolimus-eluting coronary stents in patients with acute coronary syndrome: a single-center, prospective, observational trialKCT0005187Yonsei University Health System, Yongin Severance Hospital200